Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Inclusion Criteria: * Patient able to give informed consent. * Patients \>/= 18 years with the following disease will be eligible * Newly diagnosed Ph+ ALL, previously untreated, except for the below allowances * Previously received HpyerCVAD cycle 1A+/- cycle 1B * Previously received Induction Phase 1 +/- Induction Phase II of BFM-modeled (Pediatric of Pediatric-Inspired) ALL regimen * Previously received other representative (modified from HyperCVAD, BFM, or AML-like) ALL induction course, including ABL TKI plus corticosteroid. * If the patient has received any of the above prior therapy, they may be enrolled, regardless of remission status. * Relapsed PH+ ALL, with no prior exposure to dasatinib and without known ABL kinase mutations predited to be resistant to dasatibin (e.g. L248R, L248V, Q252H, E255K, V299L, T315A, T315I, F317C, F317L, F317S, F317V) * Relapsed or refractory Ph-like ALL without prior exposure to dasatibin and with mutations or rearrangements of genes conferring sensitivity to dasatibin (ABL, CSF1R, PDGFRB) or ruxolitinib (CRLF2, JAK3, EPOR, TSLP) * Newly diagnosed or relapsed CML in lymphoid blast crisis * Confirmation of Philadelphia chromosome positivity by cytogenetics (karyotype/FISH) and/or molecular tests (BCR-ABL1 transcripts) * Acceptable end-organ function, except for documented exclusions for organ function compromise due to ALL itself * ECOG performance status ≤ 2 * Men and women of childbearing potential must be willing to p…